Clinical trials: Cisplatin
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery.
- Conditions
- Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
- Trial name
- NCT04267848
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- 1,151 sites in United States, Guam
- Volunteers
- 1,210 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the…
- Conditions
- Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
- Trial name
- NCT05058651
- Testing
- Atezolizumab, Biospecimen Collection, Carboplatin
- Where
- 265 sites in United States
- Volunteers
- 189 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Osteosarcoma, Localized Osteosarcoma
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating…
- Conditions
- High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
- Trial name
- NCT05691478
- Testing
- Bone Scan, Cabozantinib S-malate, Cisplatin
- Where
- 202 sites in United States, Australia and 2 more
- Volunteers
- 1,122 people
- Sponsor
- National Cancer Institute (NCI)
Ganglioneuroblastoma, Nodular, Neuroblastoma
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for…
- Trial name
- NCT06172296
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 180 sites in United States, Australia and 3 more
- Volunteers
- 478 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Background: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head.
- Conditions
- Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine, Neuroendocrine; Carcinoma
- Trial name
- NCT06406465
- Testing
- Belinostat, Cisplatin, Etoposide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06694454
- Testing
- azacytidine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Carcinoma, c-MET
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide.
- Trial name
- NCT06772623
- Testing
- Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab
- Where
- 127 sites in United States, Argentina and 15 more
- Volunteers
- 252 people
- Sponsor
- AbbVie
Carcinoma, Non-Small-Cell Lung
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with…
- Trial name
- NCT06875310
- Testing
- Adagrasib, Pembrolizumab, Carboplatin
- Where
- 317 sites in United States, Argentina and 33 more
- Volunteers
- 630 people
- Sponsor
- Mirati Therapeutics Inc.
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy with becotatug vedotin (MRG003) plus pucotenlimab, followed by treatment allocation based on…
- Trial name
- NCT07524413
- Testing
- Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy
- Volunteers
- 298 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases.
- Trial name
- NCT07744126
- Testing
- Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin
- Where
- 5 sites in United States, Japan and 1 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
To evaluate the efficacy and safety of ASKC202 combined with limertinib as the first-line treatment for locally advanced or metastatic NSCLC
- Conditions
- EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
- Trial name
- NCT07897188
- Testing
- ASKC202, osimertinib, pemetrexed
- Where
- China
- Volunteers
- 425 people
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
This phase I trial studies the side effects and how well surgery and heated chemotherapy with or without non-heated chemotherapy after surgery works in treating patients with ovarian, fallopian tube, uterine, or peritoneal…
- Conditions
- FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT01970722
- Testing
- Carboplatin, Cisplatin, Gemcitabine Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery.
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
- Trial name
- NCT02194738
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- 1,660 sites in United States, Guam and 1 more
- Volunteers
- 7,458 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Metastatic Bladder Cancer
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
The purpose of this study is to test the safety of the study drug, atezolizumab, when combined with the standard chemotherapy drugs, gemcitabine and cisplatin (or GC).
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma
- Trial name
- NCT02989584
- Testing
- Atezolizumab, Gemcitabine, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
This phase III trials studies whether maintenance immunotherapy (nivolumab) following definitive treatment with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (time being alive) and…
- Trial name
- NCT03811015
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Where
- 727 sites in United States
- Volunteers
- 636 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04092283
- Testing
- Carboplatin, Cisplatin, Durvalumab
- Where
- 830 sites in United States, Guam
- Volunteers
- 660 people
- Sponsor
- National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer.
- Trial name
- NCT04628767
- Testing
- Biopsy Procedure, Biospecimen Collection, Cisplatin
- Where
- 258 sites in United States
- Volunteers
- 131 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Trial name
- NCT06029270
- Testing
- Biospecimen Collection, Bone Scan, Carboplatin
- Where
- 95 sites in United States, Australia and 3 more
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
- Trial name
- NCT06835569
- Testing
- ALTA3263, cetuximab, mFOLFOX6
- Where
- 14 sites in United States
- Volunteers
- 448 people
- Sponsor
- Alterome Therapeutics, Inc.
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the…
- Conditions
- Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018
- Trial name
- NCT07061977
- Testing
- Biospecimen Collection, Brachytherapy, Carboplatin
- Where
- 345 sites in United States, Puerto Rico
- Volunteers
- 336 people
- Sponsor
- National Cancer Institute (NCI)